Juvenescence Announces Licensing Agreement with Evgen Pharma PLC
September 15, 2020
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced today a partnership with Evgen Pharma PLC to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division. JuvLife will deploy Evgen’s Sulforadex® stabilization technology to create and manufacture a nutritional health supplement containing a defined and stable dose of sulforaphane, derived from natural sources.
Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the first place. JuvLife, one of several divisions within Juvenescence, is committed to be the trusted source of scientifically proven, branded health supplements and medical foods that help increase human healthspan and overall quality of life. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors.
The license is for exclusive rights to leverage certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and Rest of World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales of the commercialized product.
Barry Clare, Executive Chairman of Evgen, said: “This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetization in an area which is outside our focus of therapeutic development in the NRF2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health supplements and brings in-depth experience in this sector. We are delighted to have them as a partner to bring the power of the sulforaphane platform to life in a non-pharmaceutical sector.”
ABOUT EVGEN PHARMA PLC
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology platform is Sulforadex®, a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
For further information, please visit: www.evgen.com
ABOUT JUVENESCENCE, LTD
Juvenescence Ltd. is a life sciences company developing therapies to modify aging — increasing human health span and longevity. It was founded by
Link to the BusinessWire press release found here.